217 related articles for article (PubMed ID: 32418846)
1. Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy: A Randomized Clinical Trial.
Kim BJ; Hunter A; Brucker AJ; Hahn P; Gehrs K; Patel A; Edwards AO; Li Y; Khurana RN; Nissim I; Daniel E; Grunwald J; Ying GS; Pistilli M; Maguire MG; Dunaief JL
Ophthalmol Retina; 2020 Sep; 4(9):889-898. PubMed ID: 32418846
[TBL] [Abstract][Full Text] [Related]
2. Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial.
Rosenfeld PJ; Dugel PU; Holz FG; Heier JS; Pearlman JA; Novack RL; Csaky KG; Koester JM; Gregory JK; Kubota R
Ophthalmology; 2018 Oct; 125(10):1556-1567. PubMed ID: 29716784
[TBL] [Abstract][Full Text] [Related]
3. Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.
Fu DJ; Bagga P; Naik G; Glinton S; Faes L; Liefers B; Lima R; Wignall G; Keane PA; Ioannidou E; Ribeiro Reis AP; McKeown A; Scheibler L; Patel PJ; Moghul I; Pontikos N; Balaskas K
JAMA Ophthalmol; 2024 Jun; 142(6):548-558. PubMed ID: 38722644
[TBL] [Abstract][Full Text] [Related]
4. Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials.
Heier JS; Pieramici D; Chakravarthy U; Patel SS; Gupta S; Lotery A; Lad EM; Silverman D; Henry EC; Anderesi M; Tschosik EA; Gray S; Ferrara D; Guymer R;
Ophthalmol Retina; 2020 Jul; 4(7):673-688. PubMed ID: 32199866
[TBL] [Abstract][Full Text] [Related]
5. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.
Holz FG; Sadda SR; Busbee B; Chew EY; Mitchell P; Tufail A; Brittain C; Ferrara D; Gray S; Honigberg L; Martin J; Tong B; Ehrlich JS; Bressler NM;
JAMA Ophthalmol; 2018 Jun; 136(6):666-677. PubMed ID: 29801123
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Subretinally Administered Palucorcel for Geographic Atrophy of Age-Related Macular Degeneration: Phase 2b Study.
Heier JS; Ho AC; Samuel MA; Chang T; Riemann CD; Kitchens JW; Slakter JS; Leiderman YI; Spencer R; Williams GA; Hickson-Curran SB; Keane M; Baldassarre JS;
Ophthalmol Retina; 2020 Apr; 4(4):384-393. PubMed ID: 32033908
[TBL] [Abstract][Full Text] [Related]
8. Relationship of Topographic Distribution of Geographic Atrophy to Visual Acuity in Nonexudative Age-Related Macular Degeneration.
Shen LL; Sun M; Ahluwalia A; Young BK; Park MM; Toth CA; Lad EM; Del Priore LV
Ophthalmol Retina; 2021 Aug; 5(8):761-774. PubMed ID: 33212271
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Geographic Atrophy from Color Photographs and Fundus Autofluorescence Images: Age-Related Eye Disease Study 2 Report Number 11.
Domalpally A; Danis R; Agrón E; Blodi B; Clemons T; Chew E;
Ophthalmology; 2016 Nov; 123(11):2401-2407. PubMed ID: 27448832
[TBL] [Abstract][Full Text] [Related]
10. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
[TBL] [Abstract][Full Text] [Related]
11. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.
Yehoshua Z; de Amorim Garcia Filho CA; Nunes RP; Gregori G; Penha FM; Moshfeghi AA; Zhang K; Sadda S; Feuer W; Rosenfeld PJ
Ophthalmology; 2014 Mar; 121(3):693-701. PubMed ID: 24289920
[TBL] [Abstract][Full Text] [Related]
12. Effect of Human Central Nervous System Stem Cell Subretinal Transplantation on Progression of Geographic Atrophy Secondary to Nonneovascular Age-Related Macular Degeneration.
Nittala MG; Uji A; Velaga SB; Hariri AH; Naor J; Birch DG; Spencer R; Leng T; Capela A; Tsukamoto A; Ip M; Sadda SR
Ophthalmol Retina; 2021 Jan; 5(1):32-40. PubMed ID: 32562884
[TBL] [Abstract][Full Text] [Related]
13. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of incident geographic atrophy in the complications of age-related macular degeneration prevention trial.
Brader HS; Ying GS; Martin ER; Maguire MG;
Ophthalmology; 2013 Sep; 120(9):1871-9. PubMed ID: 23622873
[TBL] [Abstract][Full Text] [Related]
15. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
16. Geographic Atrophy Growth Is Strongly Related to Lesion Perimeter: Unifying Effects of Lesion Area, Number, and Circularity on Growth.
Shen LL; Sun M; Ahluwalia A; Young BK; Park MM; Del Priore LV
Ophthalmol Retina; 2021 Sep; 5(9):868-878. PubMed ID: 33307218
[TBL] [Abstract][Full Text] [Related]
17. Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials.
Holekamp N; Wykoff CC; Schmitz-Valckenberg S; Monés J; Souied EH; Lin H; Rabena MD; Cantrell RA; Henry EC; Tang F; Swaminathan B; Martin J; Ferrara D; Staurenghi G
Ophthalmology; 2020 Jun; 127(6):769-783. PubMed ID: 32081489
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial.
Petrou PA; Cunningham D; Shimel K; Harrington M; Hammel K; Cukras CA; Ferris FL; Chew EY; Wong WT
Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):330-8. PubMed ID: 25525171
[TBL] [Abstract][Full Text] [Related]
19. PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kuppermann BD; Patel SS; Boyer DS; Augustin AJ; Freeman WR; Kerr KJ; Guo Q; Schneider S; López FJ;
Retina; 2021 Jan; 41(1):144-155. PubMed ID: 32134802
[TBL] [Abstract][Full Text] [Related]
20. Combined Fundus Autofluorescence and Near Infrared Reflectance as Prognostic Biomarkers for Visual Acuity in Foveal-Sparing Geographic Atrophy.
Lindner M; Nadal J; Mauschitz MM; Lüning A; Czauderna J; Pfau M; Schmitz-Valckenberg S; Holz FG; Schmid M; Fleckenstein M
Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO61-BIO67. PubMed ID: 28475704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
